OIPE JC76 APR 19 2002 PATENT & TRADEMARK OFFICE

#4

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hajime NAWATA et al

Conf. No.: **4019**

Appln. No.: **10/029,862**

Group Art Unit: **1636**

Filed: **December 31, 2001**

Examiner: **Unknown**

For: **METHOD FOR IDENTIFYING ENDOCRINE DISRUPTORS AND KIT FOR CARRYING OUT THE SAME**

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) (substitute for Form PTO-1449) form which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed no later than three months from the application's filing date for an application other than a Continued Prosecution Application (CPA) under §1.53(d) and before the mailing date of the first Office Action on the merits. Therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents,

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 10/029,862

Applicants submit herewith a partial English translation of the foreign language document, and therefore no concise explanation for such foreign language document is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: April 19, 2002

PTO/SB/08 A & B (modified)

Substitute for Form 1449 A & B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/029,862
		Confirmation Number	4019
		Filing Date	December 31, 2001
		First Named Inventor	Hajime NAWATA et al
(use as many sheets as necessary)		Art Unit	1636
		Examiner Name	Unknown
Sheet 1 of 1		Attorney Docket Number	Q-67472

OIPE APR 19 2002 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number: Number	Document Number: Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation[6]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation[6]
		Saitoh et al, *Biochem. Biophys. Res. Comm.*, 289:198-204 (2001)	
		Nishi et al, *Endocrinology*, 142(1):437-445 (2001)	
		KGN Cell Line (*http://www.rtc.riken.go.jp/cgi-bin/CELL/cell.pl?DATA=314*)	
		RGN Animal Cell Line Catalog, General Catalog No. 5-1, page 158 (May 2001)	
		Mu et al, *Mol. Cell. Endrocrin.*, 181:239-248 (2001)	
		Mu et al, *Endocrinology*, 142(8):3590-3597 (2001)	
		Mu et al, *Biochem. Biophys. Res. Comm.*, 271:710-713 (2000)	
		Ikuyama et al, *Clin. Endocrinology*, 48:647-654 (1998)	
		Nawata et al, *J. Steroid Biochem. Molec. Biol.*, 53(1-6):165-174 (1995)	
		Rainey et al, *J. of Clin. Endocrin. Metabol.*, 78(3):705-710 (1994)	
		Nawata et al, *76th Annual Meeting Program and Abstracts of the Annual Meeting-Endocrine Society,* "Aromatase Activity in Human Osteoblast-Like Osteosarcoma Cell", No. 1195 (1994)	
		Tanaka et al, *Calcif Tissue Int.*, 52:107-109 (1993)	
		Steinkampf et al, *Mol. Endocrinology*, 1(7):465-471 (1987)	
		Simms et al, *Cancer Res.*, 40:4356-4363 (1980)	
		Nawata, "Effects of Endocrine Disruptors on Aromatase Activity in the Human Ovary Granulosa-like Cell Line KGN", Endocrine Disruptors The First Symposium on Each Category, Lecture Summary (September 19, 2002)	Partial English Transl.

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to indicate here if English language Translation is attached.